新辅助化疗后腋窝放射性碘粒子置入联合前哨淋巴结活检的诊断准确性
这项前瞻性多中心非劣效诊断准确性试验在荷兰14家机构纳入212例初诊临床淋巴结阳性乳腺癌患者,评估新辅助化疗后RISAS(放射性碘粒子标记腋窝淋巴结联合前哨淋巴结活检)的诊断准确性。结果显示RISAS识别率98.2%,假阴性率3.5%,阴性预测值92.8%,均优于单纯SLNB和MARI,提示RISAS是可行性及准确性较好的微创腋窝分期方法。
要点
- RISAS识别率98.2%,假阴性率3.5%,阴性预测值92.8%
- SLNB假阴性率17.9%,阴性预测值72.8%,MARI假阴性率7.0%
- 在SLNB与MARI均成功的亚组中,RISAS假阴性率2.5%,低于SLNB的18.6%(P<.001)
核心结论
- RISAS是新辅助化疗后临床淋巴结阳性乳腺癌患者腋窝分期中最可行且准确的微创操作。
研究设计与样本
- 前瞻性、多中心、非劣效诊断准确性试验,2017年3月1日至2019年12月31日在荷兰14家机构开展。
- 纳入212例接受新辅助化疗的cT1-4且病理证实腋窝淋巴结阳性(cN1、cN2或cN3b)乳腺癌患者。
- 新辅助化疗前对病理阳性腋窝淋巴结行放射性碘粒子标记(MARI),化疗后行SLNB联合标记淋巴结切除(RISAS),随后行腋窝淋巴结清扫(ALND)。
主要发现
- RISAS识别率为98.2%(223/227),SLNB为86.4%(197/228),MARI为94.1%(224/238)。
- RISAS假阴性率为3.5%(5/144;90% CI,1.38-7.16),阴性预测值为92.8%(64/69;90% CI,85.37-97.10)。
- SLNB假阴性率为17.9%(22/123;90% CI,12.4%-24.5%),阴性预测值为72.8%(59/81;90% CI,63.5%-80.8%)。
- MARI假阴性率为7.0%(10/143;90% CI,3.8%-11.6%),阴性预测值为86.3%(63/73;90% CI,77.9%-92.4%)。
- 在174例SLNB与MARI均成功且行ALND的亚组中,RISAS假阴性率为2.5%(3/118;90% CI,0.7%-6.4%),SLNB为18.6%(22/118;90% CI,13.0%-25.5%;P < .001),MARI为6.8%(8/118;90% CI,3.4%-11.9%;P = .03)。
关键数值与推荐
- RISAS操作观察到的假阴性率非劣效界值为6.25%。
临床怎么用
- 对于新辅助化疗后临床淋巴结阳性的乳腺癌患者,可考虑采用RISAS替代腋窝淋巴结清扫进行微创腋窝分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Several less-invasive staging procedures have been proposed to replace axillary lymph node dissection (ALND) after neoadjuvant chemotherapy (NAC) in patients with initially clinically node-positive (cN+) breast cancer, but these procedures may fail to detect residual disease. Owing to the lack of high-level evidence, it is not yet clear which procedure is most optimal to replace ALND. OBJECTIVE: To determine the diagnostic accuracy of radioactive iodine seed placement in the axilla with sentinel lymph node biopsy (RISAS), a targeted axillary dissection procedure. DESIGN, SETTING, AND PARTICIPANTS: This was a prospective, multicenter, noninferiority, diagnostic accuracy trial conducted from March 1, 2017, to December 31, 2019. Patients were included within 14 institutions (general, teaching, and academic) throughout the Netherlands. Patients with breast cancer clinical tumor categories 1 through 4 (cT1-4; tumor diameter <2 cm and up to >5 cm or extension to the chest wall or skin) and pathologically proven positive axillary lymph nodes (ie, clinical node categories cN1, metastases to movable ipsilateral level I and/or level II axillary nodes; cN2, metastases to fixed or matted ipsilateral level I and/or level II axillary nodes; cN3b, metastases to ipsilateral level I and/or level II axillary nodes with metastases to internal mammary nodes) who were treated with NAC were eligible for inclusion. Data were analyzed from July 2020 to December 2021. INTERVENTION: Pre-NAC, the marking of a pathologically confirmed positive axillary lymph node with radioactive iodine seed (MARI) procedure, was performed and after NAC, sentinel lymph node biopsy (SLNB) combined with excision of the marked lymph node (ie, RISAS procedure) was performed, followed by ALND. MAIN OUTCOMES AND MEASURES: The identification rate, false-negative rate (FNR), and negative predictive value (NPV) were calculated for all 3 procedures: RISAS, SLNB, and MARI. The noninferiority margin of the observed FNR was 6.25% for the RISAS procedure. RESULTS: A total of 212 patients (median [range] age, 52 [22-77] years) who had cN+ breast cancer underwent the RISAS procedure and ALND. The identification rate of the RISAS procedure was 98.2% (223 of 227). The identification rates of SLNB and MARI were 86.4% (197 of 228) and 94.1% (224 of 238), respectively. FNR of the RISAS procedure was 3.5% (5 of 144; 90% CI, 1.38-7.16), and NPV was 92.8% (64 of 69; 90% CI, 85.37-97.10), compared with an FNR of 17.9% (22 of 123; 90% CI, 12.4%-24.5%) and NPV of 72.8% (59 of 81; 90% CI, 63.5%-80.8%) for SLNB and an FNR of 7.0% (10 of 143; 90% CI, 3.8%-11.6%) and NPV of 86.3% (63 of 73; 90% CI, 77.9%-92.4%) for the MARI procedure. In a subgroup of 174 patients in whom SLNB and the MARI procedure were successful and ALND was performed, FNR of the RISAS procedure was 2.5% (3 of 118; 90% CI, 0.7%-6.4%), compared with 18.6% (22 of 118; 90% CI, 13.0%-25.5%) for SLNB (P < .001) and 6.8% (8 of 118; 90% CI, 3.4%-11.9%) for the MARI procedure (P = .03). CONCLUSIONS AND RELEVANCE: Results of this diagnostic study suggest that the RISAS procedure was the most feasible and accurate less-invasive procedure for axillary staging after NAC in patients with cN+ breast cancer.
引用
- Simons JM, van Nijnatten TJA, van der Pol CC, et al. Diagnostic Accuracy of Radioactive Iodine Seed Placement in the Axilla With Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Node-Positive Breast Cancer. JAMA Surg. 2022. PMID: 36069889. doi:10.1001/jamasurg.2022.3907
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。